Finally, two novel agents, BMS-986458, a BCL6 degrading compound, and ARV-393, a BCL6 targeting PROTAC, are currently under clinical investigation to assess their safety and efficacy in targeting BCL6 in relapsed/refractory non-hodgkin lymphoma patients (61, 62). Here, BCL6 is linked to non-Hodgkin lymphoma.